Last reviewed · How we verify
Lastacaft (ALCAFTADINE)
Lastacaft blocks histamine at the H1 receptor to reduce allergic symptoms.
Lastacaft (Alcaftadine) is a small molecule histamine-1 receptor antagonist developed by Allergan and currently owned by Abbvie. It was FDA approved in 2010 for the treatment of allergic conjunctivitis. As a histamine-1 receptor antagonist, Lastacaft works by blocking the action of histamine at the H1 receptor, thereby reducing symptoms of allergic conjunctivitis. Lastacaft is available as a generic medication, with multiple generic manufacturers. Key safety considerations include the potential for blurred vision and eye irritation.
At a glance
| Generic name | ALCAFTADINE |
|---|---|
| Sponsor | AbbVie |
| Drug class | Histamine-1 Receptor Antagonist [EPC] |
| Target | Histamine H1 receptor |
| Modality | Small molecule |
| Therapeutic area | Other |
| Phase | FDA-approved |
| First approval | 2010 |
Mechanism of action
Alcaftadine is an H1 histamine receptor antagonist and inhibitor of the release of histamine from mast cells. Decreased chemotaxis and inhibition of eosinophil activation has also been demonstrated.
Approved indications
- Allergic conjunctivitis
Common side effects
- eye irritation
- burning and/or stinging on instillation
- eye redness
- eye pruritus
- nasopharyngitis
- headache
- influenza
Key clinical trials
- A Single-Center Evaluation of the Anti-Inflammatory Effects of Lastacaft as Measured by In-Vivo Confocal Microscopy (PHASE4)
- Safety and Efficacy of Lastacaft® for the Prevention of Itching Associated With Allergic Conjunctivitis in Korea
- A Patient Reported Ocular Comfort Assessment Comparing Bepreve to Lastacaft
- Safety and Efficacy Study of a Eye Drop for Eye Allergy (PHASE3)
- A Study to Evaluate the Efficacy of Lastacaft® Compared to Pataday™ and Placebo in Patients With Acute Allergic Conjunctivitis (PHASE4)
- Ocular Allergy Treatment Practical Impact Trial (PHASE4)
- A Study to Evaluate the Duration of LASTACAFT® in Acute Allergic Conjunctivitis (PHASE4)
- Comparison of Tolerability Between Two Allergy Drops (PHASE4)
Patents
| Patent | Expiry | Type |
|---|---|---|
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| FDA label | Mechanism, indications, dosing, boxed warnings, drug interactions |
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
| FDA Orange Book | Patents + exclusivity |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Lastacaft CI brief — competitive landscape report
- Lastacaft updates RSS · CI watch RSS
- AbbVie portfolio CI